Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + nabpaclitaxel
- Development stage
- Phase 1
- Lead developer
- Hangzhou Adlai Nortye Biopharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
buparlisib + nabpaclitaxel is a combination therapy consisting of buparlisib (BKM120), an oral pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, and nabpaclitaxel (Abraxane), an albumin-bound nanoparticle formulation of the taxane paclitaxel. Buparlisib inhibits the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in various cancers, while nabpaclitaxel disrupts microtubule function to inhibit cell division. This combination was investigated in a Phase I trial sponsored by Rutgers, The State University of New Jersey, specifically targeting patients with advanced solid tumors, with expansion cohorts for recurrent endometrial and ovarian cancers.
- Other names
- BKM120 + nabpaclitaxelbuparlisib + albumin-bound paclitaxel
02
Targets
PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CA (Phosphoinositide 3-kinase alpha)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on buparlisib + nabpaclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + nabpaclitaxel.